The Competition Commission of India clears joint venture between two healthcare companies after deciding it cannot result in any anticompetitive effects (GlaxoSmithKline / Pfizer)

The CCI cleared the proposal by GlaxoSmithKline and Pfizer to combine their global consumer healthcare businesses into a

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Shardul Amarchand Mangaldas (New Delhi)
  • Shardul Amarchand Mangaldas (New Delhi)
  • Shardul Amarchand Mangaldas (New Delhi)
  • Shardul Amarchand Mangaldas (New Delhi)
  • Shardul Amarchand Mangaldas (New Delhi)
  • Shardul Amarchand Mangaldas (New Delhi)
  • Shardul Amarchand Mangaldas (New Delhi)
  • Shardul Amarchand Mangaldas (Mumbai)
  • Shardul Amarchand Mangaldas (New Delhi)
  • Shardul Amarchand Mangaldas (New Delhi)

Quotation

Pallavi Shroff, John Handoll, Naval Satarawala Chopra, Shweta Shroff Chopra, Harman Singh Sandhu, Manika Brar, Aparna Mehra, Gauri Chhabra, Yaman Verma, Rohan Arora, The Competition Commission of India clears joint venture between two healthcare companies after deciding it cannot result in any anticompetitive effects (GlaxoSmithKline / Pfizer), 22 May 2019, e-Competitions Bulletin May 2019, Art. N° 91518

Visites 66

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues